In this context, a study involving transgenic mice showed that FOXO1 overexpression in skeletal muscles caused severe myasthenia, with the in vitro and in vivo overexpression of FOXO3 increasing the activity of the Atrogin-1 promoter to further accelerate myasthenia [9]. The gene discussed is FBXO32; the disease is Fatigable weakness.